dronabinol hemisuccinate

Dronabinol hemisuccinate is a synthetic ester prodrug of dronabinol (delta-9-tetrahydrocannabinol), the primary psychoactive constituent of cannabis. It was developed by the University of Mississippi and licensed to Skye Bioscience (formerly Nemus Bioscience) to address the pharmacokinetic limitations of oral dronabinol, such as low bioavailability and high inter-patient variability caused by extensive first-pass metabolism. Formulated as a suppository (NB1222) for rectal administration, the drug was intended to provide a more direct route to systemic circulation, potentially offering a faster onset of action and more predictable plasma concentrations. As a cannabinoid receptor agonist, it targets the CB1 and CB2 receptors to exert antiemetic and appetite-stimulant effects. While initially explored for chemotherapy-induced nausea and vomiting (CINV) and AIDS-related anorexia, the development of this specific rectal formulation has been deprioritized in favor of other cannabinoid derivatives.

Other names

THC hemisuccinatedelta-9-tetrahydrocannabinol hemisuccinatedelta9-tetrahydrocannabinol hemisuccinatedelta 9-tetrahydrocannabinol hemisuccinate